Gigaxonin is a crucial protein implicated in the cellular ubiquitin-proteasome system, playing a significant role in the regulation of intermediate filament (IF) dynamics through its involvement in the degradation pathway of IF proteins. As a member of the E3 ubiquitin ligase family, gigaxonin facilitates the ubiquitination of substrate proteins, marking them for degradation by the proteasome. This process is essential for maintaining cellular homeostasis, as it ensures the timely removal of damaged, misfolded, or otherwise unnecessary proteins from the cell. The regulation of IF proteins by gigaxonin is particularly important for neuronal health, as abnormalities in IF organization are associated with various neurodegenerative conditions. By controlling the turnover of these structural proteins, gigaxonin plays a critical role in sustaining neuronal structure and function, highlighting its importance in the nervous system's overall health and integrity.
The inhibition of gigaxonin activity disrupts the normal ubiquitination process, leading to the accumulation of its substrate proteins, including those involved in the assembly and disassembly of intermediate filaments. This accumulation can result in the aggregation of IF proteins, potentially leading to cellular dysfunction and contributing to the pathogenesis of neurodegenerative diseases. Inhibition can occur through various mechanisms, including genetic mutations that result in the production of a non-functional gigaxonin protein, post-translational modifications that alter the protein's activity or stability, or interactions with other cellular proteins that impede its ability to facilitate ubiquitination. The consequences of gigaxonin inhibition underscore the protein's pivotal role in maintaining cellular protein homeostasis. By understanding the mechanisms by which gigaxonin activity is inhibited, researchers can gain insights into the cellular processes that contribute to neurodegenerative disease progression and the maintenance of neuronal health.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A peptide aldehyde that inhibits proteasome activity, thereby affecting proteins regulated by ubiquitination, including gigaxonin. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
A naturally occurring compound that irreversibly inhibits proteasome function, which can influence gigaxonin's role in protein degradation. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A boronic acid derivative that targets and inhibits the 26S proteasome, potentially affecting gigaxonin's associated pathways. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
An epoxyketone that irreversibly inhibits the proteasome, altering the degradation processes involving gigaxonin. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
A selective and irreversible proteasome inhibitor that could affect gigaxonin's function indirectly. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
A boron-containing small molecule that selectively inhibits the 20S proteasome, which may influence gigaxonin indirectly. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
A bioavailable proteasome inhibitor that could affect the turnover of proteins regulated by gigaxonin. | ||||||